Angela B Mariotto

List of Publications by Year
in descending order

99	28,915	31949	37183
papers	citations	53	96
		h-index	g-index

99	99	99	38356
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cancer treatment and survivorship statistics, 2016. Ca-A Cancer Journal for Clinicians, 2016, 66, 271-289.	157.7	4,123
2	Cancer treatment and survivorship statistics, 2019. Ca-A Cancer Journal for Clinicians, 2019, 69, 363-385.	157.7	3,303
3	Cancer treatment and survivorship statistics, 2014. Ca-A Cancer Journal for Clinicians, 2014, 64, 252-271.	157.7	2,474
4	Cancer treatment and survivorship statistics, 2012. Ca-A Cancer Journal for Clinicians, 2012, 62, 220-241.	157.7	2,467
5	Projections of the Cost of Cancer Care in the United States: 2010-2020. Journal of the National Cancer Institute, 2011, 103, 117-128.	3.0	2,151
6	Annual Report to the Nation on the Status of Cancer, 1975â€"2014, Featuring Survival. Journal of the National Cancer Institute, 2017, 109, .	3.0	1,135
7	Annual Report to the Nation on the status of cancer, 1975â€2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer, 2014, 120, 1290-1314.	2.0	1,020
8	Cancer treatment and survivorship statistics, 2022. Ca-A Cancer Journal for Clinicians, 2022, 72, 409-436.	157.7	897
9	The Effect of Advances in Lung-Cancer Treatment on Population Mortality. New England Journal of Medicine, 2020, 383, 640-649.	13.9	893
10	Anticipating the â€œSilver Tsunamiâ€: Prevalence Trajectories and Co-Morbidity Burden among Older Cancer Survivors in the United States. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1029-1036.	1.1	833
11	Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context. Journal of the National Cancer Institute, 2009, 101, 374-383.	3.0	668
12	Cost of Care for Elderly Cancer Patients in the United States. Journal of the National Cancer Institute, 2008, 100, 630-641.	3.0	634
13	Cancer Survivors in the United States: Prevalence across the Survivorship Trajectory and Implications for Care. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 561-570.	1.1	586
14	Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2006-2014.	1.1	395
15	Adverse Events After Outpatient Colonoscopy in the Medicare Population. Annals of Internal Medicine, 2009, 150, 849.	2.0	390
16	Cancer Survivors: A Booming Population. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1996-2005.	1.1	385
17	Comparison of SEER Treatment Data With Medicare Claims. Medical Care, 2016, 54, e55-e64.	1.1	380
18	Improved Estimates of Cancer-Specific Survival Rates From Population-Based Data. Journal of the National Cancer Institute, 2010, 102, 1584-1598.	3.0	376

#	Article	IF	Citations
19	Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 809-815.	1.1	375
20	Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes and Control, 2008, 19, 175-181.	0.8	345
21	Long-Term Survivors of Childhood Cancers in the United States. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1033-1040.	1.1	303
22	Medical Care Costs Associated with Cancer Survivorship in the United States. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1304-1312.	1.1	294
23	Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. Journal of Clinical Oncology, 2019, 37, 1305-1315.	0.8	266
24	Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 566-571.	1.1	231
25	Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer, 2018, 124, 2801-2814.	2.0	200
26	Cancer Survival: An Overview of Measures, Uses, and Interpretation. Journal of the National Cancer Institute Monographs, 2014, 2014, 145-186.	0.9	197
27	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Annals of Internal Medicine, 2017, 167, 449.	2.0	160
28	Comorbidity-Adjusted Life Expectancy: A New Tool to Inform Recommendations for Optimal Screening Strategies. Annals of Internal Medicine, 2013, 159, 667.	2.0	135
29	Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999. Journal of the National Cancer Institute, 2002, 94, 1626-1634.	3.0	126
30	The prostate cancer conundrum revisited. Cancer, 2012, 118, 5955-5963.	2.0	125
31	Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits. Annals of Internal Medicine, 2014, 161, 104.	2.0	123
32	Assessing Non–Cancer-Related Health Status of US Cancer Patients: Other-Cause Survival and Comorbidity Prevalence. American Journal of Epidemiology, 2013, 178, 339-349.	1.6	120
33	When Do Changes in Cancer Survival Mean Progress? The Insight From Population Incidence and Mortality. Journal of the National Cancer Institute Monographs, 2014, 2014, 187-197.	0.9	119
34	Cancer prevalence estimates based on tumour registry data in the Surveillance, Epidemiology, and End Results (SEER) Program. International Journal of Epidemiology, 2000, 29, 197-207.	0.9	104
35	Current and Future Utilization of Services From Medical Oncologists. Journal of Clinical Oncology, 2008, 26, 3242-3247.	0.8	103
36	Is prostate cancer different in black men? Answers from 3 natural history models. Cancer, 2017, 123, 2312-2319.	2.0	100

#	Article	IF	Citations
37	Chapter 4: Changing Patterns in Breast Cancer Incidence Trends. Journal of the National Cancer Institute Monographs, 2006, 2006, 19-25.	0.9	99
38	Annual Report to the Nation on the Status of Cancer, Part 2: Patient Economic Burden Associated With Cancer Care. Journal of the National Cancer Institute, 2021, 113, 1670-1682.	3.0	97
39	Expected population impacts of discontinued prostate‐specific antigen screening. Cancer, 2014, 120, 3519-3526.	2.0	90
40	Estimation of the Acquired Immunodeficiency Syndrome Incubation Period in Intravenous Drug Users: A Comparison with Male Homosexuals. American Journal of Epidemiology, 1992, 135, 428-437.	1.6	85
41	The history and use of cancer registry data by public health cancer control programs in the United States. Cancer, 2017, 123, 4969-4976.	2.0	84
42	Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer, 2007, 109, 1877-1886.	2.0	81
43	Projections of the costs associated with colorectal cancer care in the United States, 2000–2020. Health Economics (United Kingdom), 2008, 17, 947-959.	0.8	79
44	Providing Clinicians and Patients With Actual Prognosis: Cancer in the Context of Competing Causes of Death. Journal of the National Cancer Institute Monographs, 2014, 2014, 255-264.	0.9	72
45	Projecting SEER cancer survival rates to the US: an ecological regression approach. Cancer Causes and Control, 2002, 13, 101-111.	0.8	67
46	Comparison of Approaches for Estimating Incidence Costs of Care for Colorectal Cancer Patients. Medical Care, 2009, 47, S56-S63.	1.1	66
47	Comparisons of colon–cancer survival among european countries: The eurocare study. International Journal of Cancer, 1995, 63, 43-48.	2.3	64
48	Evaluation of North American Association of Central Cancer Registries' (NAACCR) Data for Use in Population-Based Cancer Survival Studies. Journal of the National Cancer Institute Monographs, 2014, 2014, 198-209.	0.9	64
49	Improved survival time: What can survival cure models tell us about population‐based survival improvements in late‐stage colorectal, ovarian, and testicular cancer?. Cancer, 2008, 112, 2289-2300.	2.0	61
50	The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes and Control, 2012, 23, 827-835.	0.8	61
51	Breast cancer survivors in the United States. Cancer, 2009, 115, 1954-1966.	2.0	60
52	Cancer‐specific mortality, cure fraction, and noncancer causes of death among diffuse large B‐cell lymphoma patients in the immunochemotherapy era. Cancer, 2017, 123, 3326-3334.	2.0	60
53	Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000–2020. Cancer Causes and Control, 2006, 17, 1215-1226.	0.8	59
54	The efficacy of prostate‐specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer, 2018, 124, 1197-1206.	2.0	56

#	ARTICLE	IF	CITATIONS
55	Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients. Medical Care, 2016, 54, e47-e54.	1.1	55
56	Chapter 2: Dissemination of Adjuvant Multiagent Chemotherapy and Tamoxifen for Breast Cancer in the United States Using Estrogen Receptor Information: 1975-1999. Journal of the National Cancer Institute Monographs, 2006, 2006, 7-15.	0.9	52
57	Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients. Journal of Clinical Epidemiology, 2013, 66, 1376-1385.	2.4	52
58	Antineoplastic Treatment of Advanced-Stage Non–Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011). Journal of Clinical Oncology, 2017, 35, 529-535.	0.8	51
59	Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens. JAMA Network Open, 2020, 3, e200452.	2.8	49
60	Geographical, racial and socio-economic variation in life expectancy in the US and their impact on cancer relative survival. PLoS ONE, 2018, 13, e0201034.	1.1	48
61	Estimating breast cancer–specific and other–cause mortality in clinical trial and population–based cancer registry cohorts. Cancer, 2009, 115, 5272-5283.	2.0	46
62	Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. Journal of Clinical Epidemiology, 2011, 64, 1412-1417.	2.4	43
63	Burden of illness in adult survivors of childhood cancers. Cancer, 2010, 116, 3712-3721.	2.0	41
64	The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing. Statistical Methods in Medical Research, 2004, 13, 421-442.	0.7	39
65	Development of a Prognostic Model for Six-Month Mortality in Older Adults With Declining Health. Journal of Pain and Symptom Management, 2012, 43, 527-539.	0.6	39
66	An Ecologic Study of Prostate-specific Antigen Screening and Prostate Cancer Mortality in Nine Geographic Areas of the United States. American Journal of Epidemiology, 2004, 160, 1059-1069.	1.6	36
67	Survivorship for Individuals Living With Advanced and Metastatic Cancers: National Cancer Institute Meeting Report. Journal of the National Cancer Institute, 2022, 114, 489-495.	3.0	33
68	Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates. Cancer, 2002, 95, 870-880.	2.0	32
69	The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. Cancer, 2012, 118, 5652-5662.	2.0	32
70	Productivity Savings from Colorectal Cancer Prevention and Control Strategies. American Journal of Preventive Medicine, 2011, 41, e5-e14.	1.6	28
71	Comparing Cancer Care, Outcomes, and Costs Across Health Systems: Charting the Course. Journal of the National Cancer Institute Monographs, 2013, 2013, 124-130.	0.9	28
72	Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1332-1341.	1.1	28

#	Article	IF	Citations
73	Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial. Journal of the National Cancer Institute, 2020, 112, 154-160.	3.0	27
74	Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975â€2016. Cancer, 2021, 127, 4277-4286.	2.0	26
75	Lifetime Benefits and Harms of Prostate-Specific Antigenâ€"BasedÂRisk-Stratified Screening for Prostate Cancer. Journal of the National Cancer Institute, 2020, 112, 1013-1020.	3.0	23
76	The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. Journal of the National Cancer Institute, 2021, 113, 1336-1342.	3.0	22
77	The prevalence of patients with colorectal carcinoma under care in the U.S.. Cancer, 2003, 98, 1253-1261.	2.0	21
78	Geographic association between mammography use and mortality reduction in the US. Cancer Causes and Control, 2005, 16, 691-699.	0.8	20
79	Differences in Cancer Survival with Relative versus Cause-Specific Approaches: An Update Using More Accurate Life Tables. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1544-1551.	1.1	19
80	A back-calculation method to estimate the age and period HIV infection intensity, considering the susceptible population. Statistics in Medicine, 1995, 14, 1513-1530.	0.8	18
81	Current Estimates of the Cure Fraction: A Feasibility Study of Statistical Cure for Breast and Colorectal Cancer. Journal of the National Cancer Institute Monographs, 2014, 2014, 244-254.	0.9	16
82	Estimates of long-term survival for newly diagnosed cancer patients. Cancer, 2006, 106, 2039-2050.	2.0	15
83	The Impact of State-Specific Life Tables on Relative Survival. Journal of the National Cancer Institute Monographs, 2014, 2014, 218-227.	0.9	15
84	Cancer-Attributable Medical Costs for Colorectal Cancer Patients by Phases of Care: What Is the Effect of a Prior Cancer History?. Journal of the National Cancer Institute Monographs, 2020, 2020, 22-30.	0.9	15
85	Estimating the variance of cancer prevalence from population-based registries. Statistical Methods in Medical Research, 2006, 15, 235-253.	0.7	14
86	Estimating complete prevalence of cancers diagnosed in childhood. Statistics in Medicine, 2008, 27, 990-1007.	0.8	14
87	Initial Treatment for Newly Diagnosed Elderly Colorectal Cancer Patients: Patterns of Care in Italy and the United States. Journal of the National Cancer Institute Monographs, 2013, 2013, 88-98.	0.9	13
88	Advancing Comparative Studies of Patterns of Care and Economic Outcomes in Cancer: Challenges and Opportunities. Journal of the National Cancer Institute Monographs, 2013, 2013, 1-6.	0.9	12
89	Breast cancer in Portugal: Temporal trends and age-specific incidence by geographic regions. Cancer Epidemiology, 2018, 54, 12-18.	0.8	11
90	Characterizing Trends in Cancer Patients' Survival Using the JPSurv Software. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2001-2009.	1.1	9

#	Article	IF	Citations
91	Estimating life expectancy adjusted by self-rated health status in the United States: national health interview survey linked to the mortality. BMC Public Health, 2022, 22, 141.	1.2	9
92	Estimating Chemotherapy Use Among Patients With a Prior Primary Cancer Diagnosis Using SEER-Medicare Data. Journal of the National Cancer Institute Monographs, 2020, 2020, 14-21.	0.9	4
93	Using the SEER-Medicare Data to Assess Incident Chronic Myeloid Leukemia and Bladder Cancer Cases Missed by Cancer Registries. Journal of the National Cancer Institute Monographs, 2020, 2020, 31-38.	0.9	4
94	Workforce Caring for Cancer Survivors in the United States: Estimates and Projections of Use. Journal of the National Cancer Institute, 2022, 114, 837-844.	3.0	4
95	Machine Learning Methods to Identify Missed Cases of Bladder Cancer in Population-Based Registries. JCO Clinical Cancer Informatics, 2021, 5, 641-653.	1.0	3
96	Overview of US Prostate Cancer Trends in the Era of PSA Screening. , 2009, , 3-14.		3
97	Cancer prevalence by phase of care: an indicator for assessing health service needs. Tumori, 2020, 107, 030089162096183.	0.6	2
98	Impact of including second and later cancers in cause‐specific survival estimates using population‐based registry data. Cancer, 2021, , .	2.0	2
99	Analyzing discrete competing risks data with partially overlapping or independent data sources and nonstandard sampling schemes, with application to cancer registries. Statistics in Medicine, 2019, 38, 5528-5546.	0.8	1